Biogen Idec to Rearrange Drug Lineup

George Scangos, who took the helm of Biogen in July of this year, plans to focus the company’s efforts on a smaller number of drug programs and refrain from ‘dabbling’ in a wide-swath of areas. Scangos has said that Biogen, which is in late stage development of a treatment for multiple sclerosis, could target other neurological diseases such as Parkinson’s or Lou Gehrig’s disease.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail